Inclusion Criteria:

• Evidence of hepatic steatosis (≥ grade 1) at screening.
• Body mass index (BMI) ≥25 kg/m² or presence of metabolic dysfunction consistent with MASLD diagnostic criteria.
• Stable body weight (no significant weight change during the 3 months preceding enrollment).
• Willingness to maintain usual dietary habits, physical activity, and concomitant medications throughout the study.
• Ability to provide written informed consent.

Exclusion Criteria:

• Excessive alcohol consumption (>30 g/day for men or >20 g/day for women). Other known causes of chronic liver disease, including viral hepatitis (HBV or HCV), autoimmune liver disease, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, or drug-induced liver disease.
• Evidence of liver cirrhosis, hepatic decompensation, hepatocellular carcinoma, or other severe liver disorders.
• Previous bariatric surgery or planned bariatric surgery during the study period.
• Current use of medications or nutritional supplements known to significantly affect hepatic steatosis or liver function unless on a stable dose for at least 3 months before enrollment.
• Pregnancy or breastfeeding.
• Severe renal, cardiovascular, respiratory, endocrine, or malignant disease that could interfere with study participation.
• Known allergy or hypersensitivity to silybin, glutathione, vitamin E, or any component of the study product.
• Any condition that, in the investigator's judgment, could compromise participant safety or adherence to the study protocol